華潤醫藥(03320.HK)旗下別嘌醇片及格列(口奎)酮片通過一致性評價
華潤醫藥(03320.HK)公佈,旗下子公司華潤雙鶴(600062.SH)及全資子公司萬輝雙鶴收到國家藥監局頒發的別嘌醇片、格列(口奎)酮片《藥品補充申請批準通知書》,上述藥品均通過仿製藥質量和療效一致性評價。
別嘌醇片適用於患有原發性或繼發性痛風,包括急性發作,痛風石,關節破壞,尿酸結石或腎病的患者。格列(口奎)酮片適用於配合飲食和運動,改善成人2型糖尿病患者的血糖控制。
華潤醫藥指,本次別嘌醇片及格列(口奎)酮片均通過一致性評價將更有利於進一步提升產品的市場綜合競爭力及市場銷售份額,並對整體經營業績產生積極正面的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.